In a discovery that could revolutionize the treatment of depression in cancer patients, a study published in the journal Cancer reveals that a single 25 mg dose of psilocybin, the active ingredient in ‘magic mushrooms’, when combined with psychotherapy, can provide rapid and long-lasting relief from major depressive disorder (MDD) and anxiety in cancer patients.
The results, part of a two-year follow-up to a phase 2 clinical trial, suggest that psilocybin-assisted therapy may offer a potent, durable, and safe alternative to conventional antidepressants, particularly for patients grappling with the emotional toll of cancer.
“One dose of psilocybin with psychological support to treat depression has a long-term positive impact on relieving depression for as much as 2 years for a substantial portion of patients with cancer, and we’re exploring whether repeating the treatment resolves depression for more than half of the patients,” lead author Dr. Manish Agrawal, a medical oncologist and co-founder of Sunstone Therapies said in a statement.
“If randomized testing shows similar results, this could lead to greater use of psilocybin to treat depression in patients with cancer.”
Single Dose of Psilocybin Shows Lasting Antidepressant Effect
The study followed 30 cancer patients diagnosed with MDD who received a single 25 mg dose of psilocybin alongside structured psychological support in a community-based cancer center. At the two-year mark, 28 participants were evaluated, and the outcomes were striking.
More than half of the patients—53.6%—showed a significant reduction in depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale, with an average drop of 15 points. This unique approach of the study, tracking patients for two years, confirms the durability of results in a real-world, outpatient setting.
Notably, 50% of patients maintained those improvements over the whole two-year period. Anxiety symptoms also improved dramatically, with 46.4% of participants experiencing significant reductions and nearly 43% sustaining those effects.
Depression in Cancer: A Double Burden
Cancer patients frequently face psychological distress, with rates of clinical depression substantially higher than in the general population. The experience of living with a life-threatening illness, compounded by aggressive treatments and physical side effects, can profoundly affect mental health.
Traditional antidepressants often take weeks to become effective, require daily dosing, and can carry undesirable side effects. Moreover, they are not always effective for people with co-morbid physical illnesses like cancer.
However, psilocybin continues to show promise in ongoing clinical trials. A fast-acting compound that affects serotonin receptors in the brain, psilocybin has been investigated for its potential to “reset” neural circuits involved in depression and anxiety.
When combined with guided psychological support, patients often describe having a deeply meaningful experience that reshapes how they relate to themselves, their illness, and their mortality.
Building on a Growing Psychedelic Renaissance
These new findings add to a growing body of clinical research suggesting that psychedelics have powerful therapeutic value. As previously reported by The Debrief, research at institutions like Johns Hopkins University and Emory has found that psilocybin can provide rapid relief from end-of-life anxiety and depression in terminally ill patients, with benefits sometimes lasting months or even years.
In 2022, The Debrief covered a study demonstrating how psilocybin could help patients with treatment-resistant depression when administered in a controlled setting with therapeutic support. That trial, conducted by COMPASS Pathways, showed significant short-term improvements. However, it raised questions about the durability of its effects.
What sets the current study apart is its long-term perspective. Unlike many previous trials, which assessed outcomes over weeks or months, the Cancer study tracked patients for two years, confirming the durability of results in a real-world, outpatient setting.
Despite the promising results, more studies are needed to fully assess the therapeutic potential of psilocybin. While the trial was designed for safety and feasibility, the sample size was small, and the treatment occurred under tightly controlled conditions. This ongoing research is crucial for the future of psychedelic therapy.
The unique ability of psychedelic therapy to enhance quality of life and emotional well-being and even alleviate physical symptoms like pain makes it a uniquely compelling treatment option, sparking intrigue and interest in the potential of this research.
Larger, multi-site trials are now underway, including studies targeting other populations affected by major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and chronic pain. Researchers also aim to build on the promising results of the recent single-dose study. A randomized, double-blind trial is currently evaluating the effects of up to two 25 mg doses of psilocybin versus placebo in treating depression and anxiety in cancer patients.
In 2023, Oregon became the first U.S. state to legalize the supervised use of psilocybin for mental health, followed recently by Colorado. Similar programs are under development in California. However, the compound remains a Schedule I controlled substance at the federal level, complicating access and research.
Advocates of psychedelic-assisted therapy are hopeful that high-quality clinical evidence like this will drive regulatory reform and foster greater public and professional acceptance of psychedelics as legitimate medical treatments, bringing a new era of hope for mental health treatment.
As mental health challenges continue to mount across the population, the ability to provide safe, effective, and enduring treatments may be one of the most critical frontiers in medicine today.
And for cancer patients burdened with both physical and emotional suffering, a single guided journey with psilocybin might offer a rare—and much-needed—light in the dark.
Researchers described these recent findings—showing lasting improvement from a single 25 mg dose of psilocybin—as “a potentially paradigm-changing alternative to traditional antidepressants.”
Tim McMillan is a retired law enforcement executive, investigative reporter and co-founder of The Debrief. His writing typically focuses on defense, national security, the Intelligence Community and topics related to psychology. You can follow Tim on Twitter: @LtTimMcMillan. Tim can be reached by email: tim@thedebrief.org or through encrypted email: LtTimMcMillan@protonmail.com